Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors
US-12397029-B2 · Aug 26, 2025 · US
This page is not indexed by search engines while we improve data quality.
Wang Weiyi patents
Wang Weiyi is listed as an inventor on 32 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Wang Weiyi |
| Total patents | 32 |
| First publication | Jul 21, 2016 |
| Latest publication | Aug 26, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US-2025177518-A1 · Jun 5, 2025 · US
Recombinant poxviruses for cancer immunotherapy
US-2025179524-A1 · Jun 5, 2025 · US
Recombinant poxviruses for cancer immunotherapy
US-12252702-B2 · Mar 18, 2025 · US
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US-12036279-B2 · Jul 16, 2024 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US-11986503-B2 · May 21, 2024 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
US-2023310526-A1 · Oct 5, 2023 · US
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US-2023057304-A1 · Feb 23, 2023 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US-11541087-B2 · Jan 3, 2023 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
US-2022339221-A1 · Oct 27, 2022 · US
Recent patents
Latest publications not already listed above.
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US-11426460-B2 · Aug 30, 2022 · US
Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
US-2022211785-A1 · Jul 7, 2022 · US
Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US-11285209-B2 · Mar 29, 2022 · US
Recombinant poxviruses for cancer immunotherapy
US-2022056475-A1 · Feb 24, 2022 · US
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US-11253560-B2 · Feb 22, 2022 · US
Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
US-2021023151-A1 · Jan 28, 2021 · US
Vaccinia virus mutants useful for cancer immunotherapy
US-2020339959-A1 · Oct 29, 2020 · US
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US-2020316198-A1 · Oct 8, 2020 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
US-10765711-B2 · Sep 8, 2020 · US
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US-10736962-B2 · Aug 11, 2020 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
US-2020237839-A1 · Jul 30, 2020 · US
Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immume checkpoint blocking agents for solid tumors
US-2020237902-A1 · Jul 30, 2020 · US
Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
US-2020222479-A1 · Jul 16, 2020 · US
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US-10639366-B2 · May 5, 2020 · US
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US-10548930-B2 · Feb 4, 2020 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US-10512662-B2 · Dec 24, 2019 · US
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
US-2019054131-A1 · Feb 21, 2019 · US
Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
US-2019046640-A1 · Feb 14, 2019 · US
STING crystals and modulators
US-10176292-B2 · Jan 8, 2019 · US
Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immume checkpoint blocking agents for solid tumors
US-2018236062-A1 · Aug 23, 2018 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Memorial Sloan Kettering Cancer Center | 31 |
| Univ Rockefeller | 2 |
| Univ Rutgers | 2 |
| Univ Of Bonn | 1 |
| Sloan Kettering Inst Cancer | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 30 |
| A61K2039/505 | 29 |
| C07K16/2818 | 29 |
| C07K16/2827 | 29 |
| C12N2710/24132 | 26 |